Annovis Bio Inc. (NYSE: ANVS), a Phase 3 clinical-stage biotechnology company developing the investigational oral therapy buntanetap for Alzheimer's and Parkinson's diseases, announced that Founder, President and CEO Maria Maccecchini, Ph.D., will participate in two industry conferences in November. The appearances matter because they give the company a stage to outline its clinical progress and upcoming milestones to investors and potential partners at a critical time for its lead drug candidate.
At U.S. Biotech Day 2026, scheduled for Nov. 16-17 in Philadelphia, Maccecchini will join a panel discussion titled “Bridging the Translational Gap: From Discovery Insights to Clinical Proof” on Nov. 16 from 9:15-9:45 a.m. ET, followed by a company presentation from 10:15-10:30 a.m. ET highlighting Annovis’ clinical programs and upcoming milestones. The panel topic is significant because it addresses the challenge of moving early discoveries into clinical proof, a hurdle that is especially relevant for a company developing a therapy intended to modify the course of neurodegenerative disease.
Maccecchini will also present at Pharma Partnering Summit 2026, scheduled for Nov. 19-20 in Boston. Her presentation, titled “Restoring Proteostasis in Alzheimer’s and Parkinson’s Diseases with Buntanetap, a Translational Inhibitor of Neurotoxic Proteins,” will take place Nov. 19 from 11:25-11:55 a.m. ET. During both events, she will hold one-on-one meetings with biotechnology and pharmaceutical industry representatives to discuss the company’s clinical progress and potential opportunities. For a clinical-stage company, such meetings can be as important as the public presentations, since they may open the door to collaboration or licensing discussions that could help fund or accelerate development.
Annovis Bio, headquartered in Malvern, Pennsylvania, is developing treatments for neurodegenerative diseases such as Alzheimer’s disease (AD) and Parkinson’s disease (PD). Its lead drug candidate, buntanetap (formerly posiphen), is an investigational once-daily oral therapy that inhibits the translation of multiple neurotoxic proteins, including APP and amyloid beta, tau, alpha-synuclein, and TDP-43, through a specific RNA-targeting mechanism of action. By addressing the underlying causes of neurodegeneration, Annovis aims to halt disease progression and improve cognitive and motor functions in patients.
The dual-conference schedule reflects a broader effort to raise the company’s profile within the investment and partnering community. Annovis maintains an online presence through its corporate website, www.annovisbio.com, and on social channels including LinkedIn, YouTube, and X. The latest news and updates relating to ANVS are available in the company’s newsroom at https://ibn.fm/ANVS. The full press release can be viewed at https://ibn.fm/0D5yA.
MissionIR, which issued the announcement, is a specialized communications platform focused on assisting IR firms with syndicated content to enhance the visibility of private and public companies within the investment community. It is one of 75+ brands within the Dynamic Brand Portfolio @ IBN that delivers access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries. The platform also provides article and editorial syndication to 5,000+ outlets, enhanced press release enhancement to ensure maximum impact, social media distribution via IBN to millions of social media followers, and a full array of tailored corporate communications solutions.
